BC
AMAG

Birchview Capital’s AMAG Pharmaceuticals AMAG Stock Holding History

Birchview Capital’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-10,000
Closed -$152K – 55
2018
Q4 		$152K Buy
+10,000
New +$191K 0.14% 42

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $70.2B AUM 29.99% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Birchview Capital's AMAG Position: Q1 2019 in Review

Birchview Capital sold out of AMAG Pharmaceuticals (AMAG) in Q1 2019, closing a stake of 10,000 shares — an estimated $152K sold.

Birchview Capital first reported a position in AMAG in Q4 2018 and held it in 1 quarter. The position peaked at $152K in Q4 2018. 166 funds tracked by Wall St. Rank hold AMAG as of Q1 2019.

  • Birchview Capital reported no remaining AMAG Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Birchview Capital sold 10,000 AMAG Pharmaceuticals shares in Q1 2019, an estimated $152K.
  • Birchview Capital first reported a position in AMAG Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Birchview Capital's AMAG Pharmaceuticals position peaked at $152K in Q4 2018.
  • 166 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q1 2019.

Based on Birchview Capital's 13F filing for Q1 2019, filed 3 May 2019.